Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sheppy can’t even afford premium here never mind being in the premier league. 🤣🤣💯👍
Sheppy in Premier league, me non-league.
I keep in mind that news might increase sp at any time, so plough on.
B2HS2L
Currently buying the dips, how long this opportunity lasts is unknown.
God knows how long it's going to last but you must have more money than sheppy if you keep buying the dips it's pretty much like the san andreas fault ATM.Bottomless
The placing not at a discount now that’s how cheap this is with no negative material changes since Nov
Sequoia Carpets won't care at all what happens here except when the price is £50 or a takeover for £100 happens. They're VCs, their business model is chucking in £10m in to a multitude of businesses on the odds that a small percentage of them end up worth 1000x more. It's also a backward strategy of getting rid of pesky PI scum like me. My shares are safely tucked up in an ISA, much like the VC it's money I can afford to lose. I'm not going anywhere. In fact, muggins here 'topped up' yesterday.
Fuk me the ars ehole has well and truly fell out of this!!
The mechanisms employed, namely the conversion bond and raising exclusively with II’s at a huge discount (bar throwing a bone to long termers) supports that argument that they are reshaping the register. However, I don’t necessarily buy this given some of the “diamond handed” II’s that we saw participated. In addition, we’ve not seen a single tr1.
Nevertheless, this is still bargain territory and whatever the ultimate reasons for the raise, buying down here is still better than buying up at 160 by a factor of 4.
Now ask yourself why Levicept replaced their CEO with Elliott...especially when Gilde and Medicxi are key investors. These two investors have input and will be in contact with Elliott.
So why is Elliott our Chairman allowing our Executive team to make key decisions which some feel are so detrimental to the business.
Nah...it doesn't add up...
Al.
Value ,cf similar status.
Stage 1 - $1~2bn
S2 - $2-4
+3 +++
Only to the right buyer however.
Data in past t/o data.
The science looks good and inclusion of ‘neive participants ‘in the cohort gives confidence.
GLA
Yes..duff research and also not spelling out the different types of IIs. If you really want to protect the company from a low ball takeover you don't encourage certain IIs...best to look for the likes of Gilde and Medicxi to mind the doors front and back...
As you say Alcibiades,
Bachovin, Tufts Medical School, and Avacta own the patents behind PRECISION.
All three need to be satisfied by any company assuming ownership of Avacta's patent rights on purchase of Avacta.
09.04.2024 - Christina Coughlin delivered this quote in an RNS, hitting the nail on the head.
"The proof-of-concept data presented today with AVA6000 suggest that the peptide drug conjugate drug class has several key advantages, particularly the tumor-specificity of the release of doxorubicin through targeting FAP and simplicity of the manufacturing process which results in significant savings in the cost of goods."
She is discussing a market disrupting platform, and BP have been waiting for the trial to mature before showing interest.
IMO the point in time when Avacta receives FDA Approval will possibly be the catalyst for a Takeover
Currently buying the dips, how long this opportunity lasts is unknown.
Alcibiades switched allegiances during the Peloponnesian War due to his failed Sicilian Expedition, which was a huge defeat for Athens, and his upcoming trial for allegedly defacing religious statues in Athens. He also hadn't done any basic research as he thought Conifer were on the other end of the CLN and worst than that thought precision was to do with affimers.
Basic errors aside... As noted, no TR1s suggest there aren't any IIs hoovering. I'd be happy if there were. I don't think Alan making bad decisions is the most efficient or believable way of achieving it, that's just his forte. It's simpler, the bloke hates PIs, we're just liquidity. If he wants pesky PIs to have a smaller % he'll have to think bigger as the odd £10m every few years isn't doing much for the register.
'Alcibiades switched allegiances during the Peloponnesian War due to his failed Sicilian Expedition, which was a huge defeat for Athens, and his upcoming trial for allegedly defacing religious statues in Athens.'...mmmm
First, it strikes one as odd that the same management that proved itself so savvy at boosting Avacta's valuation on the back of an LFT that was very unlikely to become a commercial success now clumsily seems to hurt the valuation with every decision taken.
So, there is a possibility that their latest actions were deliberate and intended to foster a certain outcome.
One must remember that PRECISION is just a showpiece of the Affimer technology.
They have to and want to prove the ability of this novel peptide-platform to achieve things that are not possible with current antibody conjugations. Avacta is, of course, unable to develop this platform to its full potential on its own, as this will take decades and billions in R&D spending. So, we have to put up with a phenomenal proof of concept to transition the IP at the highest profit to a company that has the capabilities to carry this immense undertaking.
Bachovin, Tufts Medical School, and Avacta own the patents behind PRECISION. I don't know the details of this shared ownership. So, it was never about making a big buck on this alone. PRECISION is a proof of concept, and then the journey will continue from there on under different ownership. The greatest danger to this lies in the possibility of being taken down just before that marvelous piece de resistance shines.
PIs have no idea how to put value on Avacta adequately. Whoever thinks this is about PRECISION, you now know you have no clue how to guess a price for Avacta. On the other hand, there are the IIs who can at least guess an adequate price range for such a behemoth of IP.
For AS and other board members, this is a matter of building generational wealth, so they have to shake off those PIs, who think 3 pounds per share is a killing.
I see this series of actions in quick succession built to reduce the number of shares in the hands of people, not able to guess the value in the slightest.
Should this hold true, it makes for interesting times ahead and I have to thank the management later on, but hey we have a shared interest, so that lets me sleep well at night.
@Alcibiades, Interesting thesis. (Heights, not Conifer).
Suspect a good number of well researched, ‘sticky’, LTH’s.
Would like to see an update on the share register, at least major holdings.
Subject to above, even with ~51m new shares to II’s in the recent raise, plus existing II holdings (per last major SH update), plus management existing and (potential) +6.5m, difficult to see PI’s below ~60%+. I suspect the majority of these will be the ‘well researched LTH’s’, many of whom will be taking the opportunity to accumulate and average down (not advice, DYOR etc.).
Happy to be corrected with more reliable, sourced, numbers.
GLA
Alcibiades,
I don’t follow all the aspects of your post. For example, we are still awaiting details/TR1’s for the II who have “gobbled up” PI’s holdings.
Does “emissions” mean shares? How do we know they “went mainly to the largest IIs on board already” ?
And the convertible bond was issued to Conifer? Do you mean Heights Capital?
Can you explain why a free float will do that? What’s the financial mechanism you have in mind which sees one scenario as preferable to the other?
The answer to your rhetorical question might be pretty straightforward:
Management intends just that.
The shareholders and the free float are serious obstacles to achieving the best result in a takeover for the Board.
If management wanted to prepare their part the best they could, taking every action to reduce the free float seems reasonable.
It seems almost like management wants to kill off any PI interest and make them sell their holdings, which are then gobbled up by II. The new emissions issued at a discount? They went mainly to the largest IIs on board already. The convertible bond issued to Conifer is a great tool to reduce the free float. Now, today's move. It looks almost as if management is exerting themselves to change the shareholder structure as fast as possible. Considering that, I get the feeling many of the omnipresent, highly active, bearish opinion makers might be on the payroll of the brokerage that devised that plan. No one in his right mind would have spent that time and energy shaping a negative outlook in PI spheres to a particular stock as the usual suspects have, especially considering that management is working hand in hand with them...
Have you ever wondered why Myles stopped promoting PI investing in AVCT? A possible explanation is that he sees that now as beneficial to the future value of his holding.
Quite a sight seeing all the suckers falling for this charade.
What progress has been made in the last 12 months towards commercialising affimers.
Sorry. Did i say months. I meant years.
Moderators have deleted this this morning, wouldn't you say so Oz?
Worth repeating I'd say
Eliot Forster
“And the really cool thing about our technology and there is not many companies on the planet who have this and lots are saying we want it, is that we hit the barricade and the actual cancer cells themselves, both at the same time and that’s a very cool thing.”
PL , add to that, why is pay/benefits not linked to SP performance
I’ll stick with the same ones as last time BV:
Why was the retail appetite for supporting the business (as demonstrated by the oversubscription at 95p) not used for the raise rather than the HUGE discount given to scumbags that openly admit on podcasts hosted by clout chasing morons like Paul Hill that they're only investing for a fast buck?
What changed from the arrogance of 'don't worry about that - chuckle' to shafting all existing shareholders?
Why has the ava6k strategy changed over the course of a few weeks between the December presentation and the Turner Pope note shown to the 'investors'? Why has phase 1b re-emerged under a different name?
When will the CEO step aside so that someone with some commercial and strategic ability can ensure the future success of this business rather than the lifestyle CEO who's only talent seems to be kicking the can down the road whilst making calamitous naive embarrassing harmful decisions?
NY holding hands with the management. Probably doesn’t want management to go as they give him inside information before normal shareholders.
I have no faith in the CEO or the CFO. Neither has pharma industry experience and it shows in the poor decisions the company makes and in timelines that are rarely if ever met, resulting in loss of credibility, running low on cash and the consequently tumbling share price. Every LTH who has similar concerns about the quality of Avacta's management needs to include a question about CEO and CFO resignations. If the management receive enough, and particularly if they are deluged with such questions, then they will not only be fully aware of PI feeling and but will have to respond. Won't they?